Cargando…
SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88
BACKGROUND: Resistance to trastuzumab has become a leading cause of mortality in breast cancer patients and is one of the major obstacles for improving the clinical outcome. Cell behavior can be modulated by long non-coding RNAs (lncRNAs), but the contribution of lncRNAs in trastuzumab resistance to...
Autores principales: | Dong, Huaying, Wang, Wei, Mo, Shaowei, Chen, Ru, Zou, Kejian, Han, Jing, Zhang, Fan, Hu, Jianguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114182/ https://www.ncbi.nlm.nih.gov/pubmed/30157918 http://dx.doi.org/10.1186/s13046-018-0875-3 |
Ejemplares similares
-
Retraction Note: SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88
por: Dong, Huaying, et al.
Publicado: (2023) -
EIF4A3 stabilizes the expression of lncRNA AGAP2‐AS1 to activate cancer‐associated fibroblasts via MyD88/NF‐κb signaling
por: Xu, Qingqing, et al.
Publicado: (2022) -
MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer
por: Silasi, Dan-Arin, et al.
Publicado: (2007) -
MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity
por: Saikh, Kamal U.
Publicado: (2021) -
Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88‐Dependent Inflammation
por: Luo, Wu, et al.
Publicado: (2022)